RNS Number : 1156I
LungLife AI, INC
03 August 2023
 

 

LungLife AI, Inc.
(the "Company" or "LungLife")

 

Notice of Results

Investor Presentation

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2023 on Tuesday 8 August 2023.

 

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial Officer, will be hosting a live online presentation relating to the half-year report via the Investor Meet Company platform at 4.30pm (BST) on Tuesday 8 August 2023.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here. Investors who already follow LungLife on the Investor Meet Company platform will automatically be invited.

 

A recording of the presentation and a PDF of the slides used will also be available on the LungLife website: https://investors.lunglifeai.com/media/

 

 

For further information please contact:

 

LungLife AI, Inc.

www.lunglifeai.com

Paul Pagano, CEO 

Via Walbrook PR

David Anderson, CFO

 

 

 

Investec Bank plc (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7597 5970

Virginia Bull / Cameron MacRitchie / Lydia Zychowska


 

Goodbody (Joint Broker)

Tom Nicholson / Stephen Kane

 

 

Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

Walbrook PR Limited

 Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com

Paul McManus / Alice Woodings / Phillip Marriage

Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 


About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSSFFIEEDSEDA